Clinical trial
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally…
NCT00252798 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00252798 |
|---|---|
| Title | ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer |
| Official title | A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug, Procedure |
| Interventions | Gefitinib, Carboplatin, Paclitaxel, Radiation |
| Enrollment | 44 |
| Start date | Jul 1, 2002 |
| Completion | Oct 1, 2005 |
| First posted | Nov 15, 2005 |
| Last update posted | Dec 19, 2007 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: